Advocacy Campaigns

Current advocacy campaigns

Have your say on PBS listings for IBD Medications

The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on guselkumab (Tremfya®) which is a revised application for the first drug of a new class of biologics in IBD (IL-23 inhibitor) or biosimilar versions of ustekinumab (Yesintek® and  Steqeyma®) then send us an email about what difference it has made/would make to your life if listed on the PBS: [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 18 May 2026.

For information about the PBS meeting visit the PBAC meeting page on the PBS website.

Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)	Drug Type and Use (What is the drug used to treat?)	Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)
GUSELKUMAB Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen Injection 100 mg in 1 mL single use pre-filled syringe Injection 200 mg in 2 mL single use pre-filled syringe Tremfya® JANSSEN-CILAG PTY LTD New PBS listing PBS General Schedule PBS Section 100 (Highly Specialised Drugs Program)	Severe Crohn disease (CD)	To consider the sponsor’s revised proposal for listing guselkumab for the treatment of adult patients with severe CD who have failed to achieve an adequate response to prior systemic therapy (i.e. corticosteroids and at least 3 months of immunosuppressive therapy). This item was previously recommended by the PBAC at its July 2025 meeting. Authority Required (Written)
USTEKINUMAB Injection 45 mg in 0.5 mL vial Injection 45 mg in 0.5 mL single use pre-filled pen Injection 90 mg in 1 mL single use pre-filled pen Steqeyma® CELLTRION HEALTHCARE AUSTRALIA PTY LTD New PBS listing PBS General Schedule	Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease Moderate to severe ulcerative colitis	To request listing of new forms of the Steqeyma biosimilar brand of ustekinumab that mirror the originator brand’s current listings with equivalent forms and strengths. Authority Required
USTEKINUMAB Injection 45 mg in 0.5 mL Injection 45 mg in 0.5 mL single use pre-filled syringe Injection 90 mg in 1 mL single use pre-filled syringe Solution for I.V. infusion 130 mg in 26 mL Yesintek® GENERIC HEALTH PTY LTD New PBS listing PBS General Schedule PBS Section 100 (Highly Specialised Drugs Program)	Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease Moderate to severe ulcerative colitis	To request listing of a new ustekinumab biosimilar that mirrors the originator brand’s current listings. Authority Required